vm4-037
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00884520)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- (18f)vm4-037
- 18f vm4-037
- 18f vm4-037
- 3-(4-(2-(f-18)fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1h-1,2,3-triazol-1-yl)butanamido)propanoic acid
- 3-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1h-1,2,3-triazol-1-yl)butanamido)propanoic acid
- vm4-037
- vm4-037
- vm4-037
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01712685 | Phase 2 | Oct 1, 2012 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00935142 | Phase 1 | Jan 1, 2012 | Maastricht University |
| NCT00884520 | Early Phase 1 (Phase 1) | Apr 1, 2009 | Siemens, Temple University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maastricht University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2012 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2012 |
| Siemens | For profit | 1 | 1 | 1 | 2009 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1